Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod
by Zacks Equity Research
J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
by Zacks Equity Research
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Allergan (AGN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Allergan (AGN) delivered earnings and revenue surprises of 3.37% and 1.99%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.
Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results
by Zacks Equity Research
Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III
by Zacks Equity Research
Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders
by Zacks Equity Research
Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Bull of the Day: Editas Medicine (EDIT)
by Kevin Cook
CRISPR gene editing is going to transform the world and this leader just won key patent battles to capitalize
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
by Zacks Equity Research
Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.
Allergan Drops, Stops Textured Breast Implant Sales in Europe
by Zacks Equity Research
Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.
Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
by Zacks Equity Research
Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.
Okta (OKTA) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Okta's (OKTA) third-quarter fiscal 2019 results benefit from increasing adoption of the company's Identity solutions.
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
by Zacks Equity Research
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
Why Is Allergan (AGN) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
by Zacks Equity Research
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.